InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
16,886.00
(
-0.57%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
83.45
(
-2.85%
)
Bitcoin
57,274.46
(
-5.49%
)
Post# of 251667
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119533
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 119352

Wednesday, 05/04/2011 2:34:31 PM

Wednesday, May 04, 2011 2:34:31 PM

Post# of 251667

YMI/INCY—If they have to go head-to-head then they are faced with the murkiness of a non-inferiority trial…

What kind of murkiness are you referring to?

…and in addition they will probably have to pay the (doubtless obscene) price that INCY will be charging for ruxolitinib for the patients in the comparator arm.

It’s doubtful, IMO, that this will be a material consideration in the overall scheme of things given the typical clinical costs of a phase-3 oncology program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up